LILRB4 regulates circadian disruption-induced mammary tumorigenesis via non-canonical WNT signaling pathway

Olajumoke Ogunlusi, Mrinmoy Sarkar, Kayla Carter, Arhit Chakrabarti, Devon J. Boland, Tristan Nguyen, James Sampson, Christian Nguyen, Danielle Fails, Yava Jones‐Hall, Loning Fu, Gus A. Wright, Da Mi Kim, James J. Cai, Bani K. Mallick, Alex C. Keene, Jeff R. Jones, Tapasree Roy SarkarOncogene 2025 · DOI

Abstract

Epidemiological studies have long associated circadian rhythm disruption (CRD)—often caused by shift work or chronic jet lag—with an increased risk of breast cancer. However, the precise mechanisms by which a disrupted internal clock influences mammary gland morphology and drives aggressive basal-like tumorigenesis have remained elusive. This study identifies the immune receptor LILRB4 as a critical mediator. Chronic CRD was found to disrupt mammary gland architecture, promote an immunosuppressive tumor microenvironment (TME), and accelerate lung metastasis by upregulating LILRB4 via a non-canonical WNT signaling pathway. Furthermore, targeted immunotherapy against LILRB4 was shown to reverse these effects, highlighting a novel therapeutic strategy for CRD-associated cancers.

Introduction

Aggressive triple-negative breast cancer (TNBC) is known for its poor prognosis and limited therapeutic options. While environmental factors like sleep disruption are linked to TNBC risk, the molecular "bridge" between systemic circadian disruption and local tumor progression has been a missing piece of the puzzle. This research investigates how chronic jet lag alters the mammary gland's physical structure and immune landscape, identifying LILRB4 as the key driver of this transformation.

Establishing the Circadian Disruption Model

To simulate chronic circadian disruption, researchers utilized a mouse model subjected to an 8-hour light phase advance every two days, mimicking permanent jet lag. This protocol successfully disrupted the rhythmic expression of core clock genes such as Bmal1, Per1, and Cry1 in mammary tissues.

Comprehensive overview of the circadian disruption (CRD) model, including the light/dark schedule, actograms of mouse activity, and the resulting disruption of core clock gene expression and mammary gland morphology.

Morphological Sabotage and Accelerated Tumorigenesis

One of the study's most striking findings was that CRD causes physical damage to the mammary gland even before tumors appear. Chronic disruption led to ductal hyperplasia and a breakdown of the protective myoepithelial cell layer. Quantitatively, CRD mice showed a significant reduction in mammary branching and terminal end buds, paired with a sharp increase in cellular proliferation (Ki67+ cells).

Quantitative data demonstrating that CRD significantly reduces the number of branches and terminal end buds while increasing the percentage of Ki67-positive proliferating cells in the mammary gland.

In genetically engineered mouse models (GEMM) of aggressive breast cancer, these morphological changes translated to faster tumor initiation. Tumors in CRD-exposed mice appeared at 18 weeks, compared to 22 weeks in control mice on a normal light/dark cycle. Furthermore, CRD significantly increased the metastatic burden in the lungs.

Turning Tumors "Cold": The Role of LILRB4

Using single-cell RNA sequencing (scRNA-seq), the team discovered that CRD shifts the tumor microenvironment from an immune-active ("hot") state to an immunosuppressive ("cold") state. This shift is characterized by an increase in M2-like macrophages and Regulatory T cells (Tregs), which protect the tumor from immune attack.

Central to this process is LILRB4 (Leukocyte Immunoglobulin-Like Receptor B4). The study found that CRD upregulates LILRB4, which in turn activates a non-canonical WNT signaling pathway (involving pJNK and c-FOS). This pathway promotes the expansion of cancer stem cells and the recruitment of immunosuppressive cells.

Therapeutic Potential

The researchers tested whether blocking LILRB4 could mitigate the effects of circadian disruption. Treatment with an anti-LILRB4 antibody in CRD mice successfully:

  • Reduced the number of lung metastatic foci.
  • Inhibited the immunosuppressive Treg population.
  • Restored the activity of "killer" CD8+ T cells.

These results suggest that LILRB4-targeted immunotherapy could be a powerful tool for treating patients whose cancers are driven or exacerbated by circadian disruption.

Conclusion

This study establishes LILRB4 as a definitive link between a broken internal clock and aggressive mammary tumorigenesis. By identifying the LILRB4-WNT axis, the research provides both a molecular explanation for epidemiological observations and a promising new therapeutic target to combat the metastatic spread of breast cancer in the context of modern, sleep-disrupted lifestyles.

Reference: Ogunlusi, O., Sarkar, M., et al. LILRB4 regulates circadian disruption-induced mammary tumorigenesis via non-canonical WNT signaling pathway. Oncogene (2025).

Summary updated

Abstract

Epidemiological studies have shown that circadian rhythm disruption (CRD) is associated with the risk of breast cancer. However, the role of CRD in mammary gland morphology and aggressive basal mammary tumorigenesis and the molecular mechanism underlying CRD-induced carcinogenesis remain unknown. To investigate the effect of CRD on aggressive tumorigenesis, a genetically engineered mouse model of aggressive breast cancer was used. The impact of CRD on the tumor microenvironment was investigated using the tumors from LD12:12 and CRD mice via scRNA-seq, flow cytometry, multiplexing immunostaining, and realtime PCR. The effect of LILRB4-immunotherapy on CRD-induced tumorigenesis was also investigated. Here we investigated and identified the impact of CRD on basal tumorigenesis and mammary gland morphology. We found that chronic CRD disrupted mammary gland morphology, increased lung metastasis, and induced an immunosuppressive tumor microenvironment by enhancing LILRB4 expression. Furthermore, targeted immunotherapy against LILRB4 reduced CRD-induced immunosuppressive microenvironment and lung metastasis. Finally, we showed that LILRB4 regulates CRD-induced mammary tumorigenesis via a non-canonical WNT signaling pathway. These findings identify and implicate LILRB4 as a link between CRD and aggressive mammary tumorigenesis and establish the potential role of the targeted LILRB4a immunotherapy as an inhibitor of CRD-induced lung metastasis.
BibTeX
@inproceedings{ogunlusi2025lilrb,
  author = {Olajumoke Ogunlusi and Mrinmoy Sarkar and Kayla Carter and Arhit Chakrabarti and Devon J. Boland and Tristan Nguyen and James Sampson and Christian Nguyen and Danielle Fails and Yava Jones‐Hall and Loning Fu and Gus A. Wright and Da Mi Kim and James J. Cai and Bani K. Mallick and Alex C. Keene and Jeff R. Jones and Tapasree Roy Sarkar},
  title = {{LILRB4 regulates circadian disruption-induced mammary tumorigenesis via non-canonical WNT signaling pathway}},
  booktitle = {Oncogene},
  year = {2025},
  doi = {10.1038/s41388-025-03597-5},
}
Figure